Zacks.com on MSN17h
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...
eLife12h
Early and delayed STAT1-dependent responses drive local trained immunity of macrophages in the spleen
In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.
pharmaphorum18h
J&J files intravesical bladder cancer drug TAR-200 in US
J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...
tnp.straitstimes6h
Combo of ‘off-label’ chemo drugs successfully fights bladder cancer
A combination of two existing chemotherapy drugs has been used to fight bladder cancer successfully for the first time in ...